TGA Archives - Insight

Eyerising Myopia Management Device granted TGA approval for home-use red-light therapy

Medtech company Eyerising International Pty Ltd has announced its myopia management device – based on repeated low-level red-light (RLRL) technology that can be used at home – has been approved by the Australian Therapeutic Goods Administration (TGA).
Read More

rhiannon bowmanAugust 3, 2023, 2:32 pmAugust 3, 2023

Eye disease AI screening system TGA-approved

The Therapeutic Goods Administration (TGA) has approved a new AI software system that can screen for three major eye diseases in primary care settings.
Read More

pcm_adminApril 26, 2022, 9:34 amJuly 21, 2023

Low-dose atropine EIKANCE secures first myopia TGA approval

The Therapeutic Goods Administration (TGA) has approved EIKANCE 0.01%, Australia’s first low-dose atropine eye drop for myopia progression in children and young teenagers.
Read More

pcm_adminMarch 18, 2022, 9:40 amJuly 21, 2023

Lucentis now TGA-approved for retinopathy of prematurity

The Therapeutic Goods Administration (TGA) has granted Lucentis (ranibizumab) an indication for retinopathy of prematurity (ROP), making it the first anti-VEGF therapy approval for the rare disease affecting premature infants in Australia.
Read More

pcm_adminMarch 1, 2022, 1:19 pmJuly 21, 2023

TGA approves Luxturna gene therapy

In a historical development for the eye health sector, the Therapeutics Goods Administration (TGA) has approved the country’s first true gene therapy, indicated for a rare form of inherited retinal disease (IRD).
Read More

Myles HumeAugust 26, 2020, 9:29 amJuly 21, 2023

TGA

Eyerising Myopia Management Device granted TGA approval for home-use red-light therapy

Eye disease AI screening system TGA-approved

Low-dose atropine EIKANCE secures first myopia TGA approval

Lucentis now TGA-approved for retinopathy of prematurity

TGA approves Luxturna gene therapy

Connect With Us

Join The Newsletter

Popular Topics

About Insight